For two decades, America’s overdose curve moved in one direction. Every year the number climbed, and every year the climb felt permanent. When the first decline came, it was easy to read as a pause — a single breath before the line resumed its rise.
By 2025, the pattern was harder to dismiss. Three consecutive years of decline now sit where the ascent used to be, and with them the clearest evidence yet that the curve has genuinely bent.
Preliminary CDC figures record 69,973 overdose deaths in 2025 — deaths from all drugs, opioids and stimulants alike. That is roughly 14% fewer than the year before, and about 35% below the 2022 peak, when the yearly toll neared 108,000.
Final NVSS counts through 2023; predicted provisional 2024–2025 (May 13, 2026 release), dashed and open. Source: CDC NCHS.
Deaths involving synthetic opioids, chiefly fentanyl, remain just over half of the total, and they fell fastest: a decline nearly the size of the country’s entire drop.
2024: the first year in the record when every class fell. Final data through 2024; 2025 predicted provisional (June 2026), open circles. Categories overlap — never summed. Hover a line to isolate it.
The progress is real, but uneven. Eight states moved the other way in the most recent count; New Mexico, Arizona, and Colorado each rose by 10% or more, even as most of the country fell. A national curve bending downward still holds local curves that climb.
12 months ending December 2025 vs. a year earlier; June 2026 extract, occurrence-based, provisional. Hover any state. US average −13.7%.
Open dots: four rising states each predict fewer than 175 deaths — small numbers swing percentages. The West peaked about a year after the rest of the country; its curve is behind, not broken.
No single cause owns the reversal. Naloxone became easier to carry and easier to reach. Barriers to treatment eased. A disrupted, sometimes less potent fentanyl supply may have played its part. And awareness deepened in quiet, practical ways: test strips, counterfeit-pill warnings, the discipline of never using alone — each one making risk more visible, and survival more possible.
Events verified against SAMHSA, FDA, DEA, and the Federal Register. Treatment gap: NSDUH via Health Affairs / SAMHSA; exact pooled percentage to be confirmed before print.